Orchestra BioMed Holdings (OBIO) EBITDA (2022 - 2025)
Historic EBITDA for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$20.8 million.
- Orchestra BioMed Holdings' EBITDA fell 3589.68% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 3067.53%. This contributed to the annual value of -$61.0 million for FY2024, which is 2410.33% down from last year.
- Per Orchestra BioMed Holdings' latest filing, its EBITDA stood at -$20.8 million for Q3 2025, which was down 3589.68% from -$19.4 million recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' EBITDA registered a high of -$5.7 million during Q1 2022, and its lowest value of -$20.8 million during Q3 2025.
- Over the past 4 years, Orchestra BioMed Holdings' median EBITDA value was -$13.3 million (recorded in 2023), while the average stood at -$13.5 million.
- Per our database at Business Quant, Orchestra BioMed Holdings' EBITDA tumbled by 9142.96% in 2023 and then plummeted by 1510.12% in 2024.
- Orchestra BioMed Holdings' EBITDA (Quarter) stood at -$9.8 million in 2022, then crashed by 30.67% to -$12.8 million in 2023, then decreased by 27.06% to -$16.2 million in 2024, then decreased by 28.38% to -$20.8 million in 2025.
- Its EBITDA was -$20.8 million in Q3 2025, compared to -$19.4 million in Q2 2025 and -$18.8 million in Q1 2025.